NCT07015853 - ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions

TNBC - Triple-Negative Breast CancerBreast Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance.

RADIATION

Radiotherapy

RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2;

DRUG

Axatilimab

Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.

Trial Locations (1)

Cedars-Sinai Medical Center, Los Angeles